Location History:
- Schlieren, CH (2016)
- Zürich, CH (2017 - 2019)
- Zurich, CH (2015 - 2022)
Company Filing History:
7 out of 7 
4 out of 16 
1 out of 257 
Years Active: 2015-2022
Title: The Innovative Journey of Dragan Grabulovski in the Field of Biochemistry
Introduction
Dragan Grabulovski, located in Zurich, Switzerland, is a notable inventor with a focus on biochemistry and molecular biology. With an impressive portfolio of 13 patents, he has contributed to the advancement of scientific understanding and therapeutic techniques, particularly in the realm of fibroblast growth factors and binding proteins.
Latest Patents
Among Dragan Grabulovski's latest inventions are the FGFR3 binding molecules, which relate to polypeptides that bind to fibroblast growth factor receptor 3 isoforms 3b and 3c (FGFR3b and FGFR3c). The polypeptides involve a unique amino acid sequence with specific criteria for amino acid identity and conservation, reflecting targeted innovation in binding affinity and specificity.
Another noteworthy patent involves the development of specific and high-affinity binding proteins that incorporate modified SH3 domains derived from the FYN kinase. This innovation includes a library of recombinant derivatives with notable sequence identity, aimed at enhancing binding capabilities to non-natural ligands. These advancements showcase Dragan's deep understanding of molecular interactions and protein engineering.
Career Highlights
Dragan Grabulovski's career is marked by significant contributions to leading research institutions and companies. He has worked at Covagen AG, a biopharmaceutical company focusing on innovative biotherapeutics, and the ETH Zurich, which is renowned for its cutting-edge research and education in science and technology. His role in these organizations has allowed him to leverage his expertise in biochemistry to develop groundbreaking inventions.
Collaborations
Throughout his career, Dragan has collaborated with notable colleagues such as Julian Bertschinger and Richard Woods, contributing to a dynamic research environment that fosters innovation. These collaborations have further enhanced his ability to push the boundaries of current scientific knowledge and develop new therapeutic approaches.
Conclusion
Dragan Grabulovski exemplifies the spirit of innovation in the scientific community with his extensive patent portfolio and collaborative work in biochemistry. His latest patents represent significant advancements in the field, highlighting the potential of targeted therapeutic strategies. As he continues to explore new frontiers in research, Dragan remains a prominent figure in biochemistry and inventions that could shape future medical therapies.